INTENTION TO FLOAT

Question: Are you currently located in Switzerland?:

The information contained on the following web pages is intended for Swiss residents who are physically located in Switzerland. In particular, the information contained in this section of Galderma website is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the "United States"), Canada, Australia and Japan, or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction, and does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any ordinary shares or other securities of the Company in the United States, Canada, Australia, Japan or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.

The shares of the Company referred to on this website (the "Shares") have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There is no intention to register any Shares referred to herein in the United States or to make a public offering of the Shares in the United States. Any Shares sold in the United States will be sold only to persons reasonably believed to be qualified institutional buyers (as defined in Rule 144A under the Securities Act) in reliance on Rule 144A under the Securities Act.

The Shares have also not been and will also not be registered under the applicable securities laws of Canada, Australia or Japan and, subject to certain exemptions, may not be offered or sold in or into or for the account or benefit of any person having a registered address in, or located or resident in Canada, Australia or Japan. There will be no public offer of the Shares in Canada, Australia or Japan.

Access to the information and documents contained on the following websites may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such information and documents. All persons residing outside of Switzerland who wish to have access to the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been obtained outside Switzerland. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.

I therefore certify that:

• I am resident and physically present in Switzerland and
• I have read, understand and agree to comply with all of the restrictions set forth above.

Question: Are you currently located in the United States of America, Canada, Japan or Australia?:

The information contained in this section of Galderma website is restricted to persons resident and physically present in Switzerland. In particular, it is not for release, publication or distribution, directly or indirectly, in whole or in part in, into or from the United States of America (including its territories and possessions), any state of the United States and the District of Columbia (the “United States”), Canada, Australia and Japan or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.

IMPORTANT INFORMATION

You have indicated that you are not located in Switzerland, United States, Canada, Japan or Australia. These materials are not intended for, directed at or accessible by persons located outside Switzerland. However, persons located in jurisdictions other than the United States that make the below certifications can access these materials. Please read the certifications below carefully and provide the information requested in order to receive these materials. If you cannot make the below certifications, please exit this page:

For users located within the EEA

“We are located or resident in a member state of the European Economic Area ("EEA") in which the Prospectus Regulation is applicable (each, a "Relevant Member State") and are 'qualified investors' within the meaning of Article 2(e) the Prospectus Regulation ("Qualified Investors"). For these purposes, the expression "Prospectus Regulation" means Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC. Further, if we are acting as a fiduciary or agent for one or more investor accounts, (a) each such account is a Qualified Investor, (b) we have investment discretion with respect to each account, and (c) we have full power and authority to make the representations, warranties, agreements and acknowledgements herein on behalf of each such account.”

By clicking “AGREE” below, you are certifying that the certifications and information provided are true and accurate, that you would like to access the materials. You agree that the materials you receive are for your own use and will not be released, published or distributed to any person (other than persons in your organisation who are not located or resident in the United States, Australia, Canada, Japan or any other jurisdiction in which it would be unlawful to do so).

For users located within the UK

We are located or resident in the United Kingdom and are persons who are “qualified investors” within the meaning of Article 2 of Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 who are also (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”).The shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such shares will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

By clicking “AGREE” below, you are certifying that the certifications and information provided are true and accurate, that you would like to access the materials. You agree that the materials you receive are for your own use and will not be delivered, released, published or distributed to any person (other than persons in your organisation who are not located or resident in the United States, Australia, Canada, Japan or any other jurisdiction in which it would be unlawful to do so).

For users outside the US, the UK and EEA who are able, under locally applicable law, to access the materials

“We confirm that we are an institutional investor and are not located or resident in the United States, Australia, Canada, Japan or any jurisdiction in which it would be unlawful for us to access the prospectus (the “Prospectus”) and other offer materials published by Galderma in connection with its initial public offering of ordinary shares which are available on this website (the “Offer Materials”). We confirm that our accessing the Offer Materials, including the Prospectus, is lawful and in accordance with the laws of the jurisdiction in which we are located or resident and we confirm that we will not, nor are we authorised to, deliver, release, publish or distribute the Prospectus or the other Offer Materials, electronically or otherwise, in or into any jurisdiction or to any other person.”

By clicking “AGREE” below, you are certifying that the certifications and information provided are true and accurate, that you would like to access the materials. You agree that the materials you receive are for your own use and will not be delivered, released, published or distributed to any person (other than persons in your organisation who are not located or resident in the United States, Australia, Canada, Japan or any other jurisdiction in which it would be unlawful to do so).

Your data will be held by Galderma and processed only to ensure our compliance with applicable regulations.

We regret that, due to regulatory restrictions, we are unable to provide you with access to this section of our website.